ペメトレキセド再投与とベバシズマブ併用療法の安全性と有効性

基本情報

NCT ID

NCT02200354

ステータス

中止

試験のフェーズ

第2相

試験タイプ

介入

目標被験者数

20

治験依頼者名

Kobe City General Hospital

概要

For patients with nonsquamous NSCLC and a good performance status (PS), pemetrexed and cisplatin has been recommended for first-line NSCLC treatment. Recently, results from the PARAMOUNT trial showed that patients with nonsquamous NSCLC who had a good PS and had not progressed after completing four cycles of pemetrexed-cisplatin induction therapy benefitted from pemetrexed continuation maintenance therapy. Furthermore, pemetrexed with bevacizumab continuous maintenance might be better treatment option, considering the results from AVAPEARL trial. Pemetrexed rechallenge has been reported to be effective in some patients. Therefore, in order to investigate the safety and efficacy of pemetrexed rechallenge with bevacizumab,we conducted this study.

対象疾患

介入

依頼者（Sponsor）

実施施設 (1)